Glivec® International Patient Assistance Program (GIPAP)
The Glivec® International Patient Assistance Program (GIPAP) is one of the most comprehensive and far-reaching cancer access programs ever developed on a global scale. Since its implementation in early 2002, GIPAP has provided Glivec® to more than 49,000 patients in 80 developing countries with minimal reimbursement capabilities who would not otherwise have access to the drug to treat their life-threatening diseases.
Unlike traditional donation programs that deliver drugs through hospitals or other third party distribution organizations, GIPAP’s “direct-to-patient” model delivers/dispenses Glivec® directly to patients by their treating physician/pharmacist. Currently, there is no other global cancer program like it in existence. Its success is due in large part to its ability to adapt program goals to local rules/ regulations.
Novartis designed GIPAP to provide Glivec® (imatinib) free of cost to eligible patients in developing countries who meet specific medical and socio-economic guidelines. Through The Max Foundation, GIPAP also provides information and referral assistance to patients, their family members and caregivers.
GIPAP is more than a drug donation program; its goal is to optimize successful Glivec® treatment by providing patients with emotional support and increasing awareness within their communities.
The Max Foundation, as Novartis’ main partner in the administration of GIPAP®, provides socio-economic evaluation of patients, guides physicians through the patient evaluation process, and provides emotional support, information and referral assistance to patients, their family members and care givers. In addition, we monitor patients to support the highest standard of patient care, collaborate with Novartis to identify and qualify eligible medical centers and physicians worldwide, and protect confidential patient information and data received in the course of program administration.
Through The Max Foundation’s partnership with Novartis, experienced physicians and local organizations, GIPAP has been able to reach patients who would otherwise not have access to Glivec for their life-threatening diseases.